Article
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
British journal of cancer - 17 Mar 2015
Price T J, Bruhn M A, Lee C K, Hardingham J E, Townsend A R, Mann K P, Simes J, Weickhardt A, Wrin J W, Wilson K, Gebski V, Van Hazel G, Robinson B, Cunningham D, Tebbutt N C
Abstract excerpt
BACKGROUND: Mutations affecting RAS genes are now established predictive markers of nonresponse to anti-EGFR antibodies in advanced CRC. This analysis assessed the prognostic and predictive impact of extended RAS and PIK3CA gene mutation status in patients receiving capecitabine plus or minus bevacizumab (±mitomycin C) in the randomised phase III MAX study. METHODS: DNA was extracted from archival macrodissected...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.